Search results
Merck & Co Inc (MRK) Sits And Waits For Direction At $131.30 Price – Stocks Register
Stocks Register· 2 days agoMerck & Co Inc (NYSE:MRK) at last check was buoying at $131.30 on Thursday, May 23 with a rise of 0.15% from its closing price on previous day. Taking a ...
Merck & Co., Inc. (NYSE:MRK) is a favorite amongst institutional investors who own 79%
Simply Wall St. via Yahoo Finance· 2 days ago(NYSE:MRK), it is important to understand the ownership structure of the business. We can see that...
Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday?
Benzinga via Yahoo Finance· 1 hour agoKeytruda (pembrolizumab) is Merck & Co Inc’s (NYSE:MRK) top selling cancer drug. The abstract...
MRK Stock Sees Decline of Approximately
Knox Daily· 2 days agoThe buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Merck & Co Inc shares valued ...
ASCO 2024: Merus touts positive Phase II data for head and neck cancer antibody
Pharmaceutical Technology via Yahoo Finance· 8 hours agoThe Phase II study is evaluating petosemtamab in combination with Merck & Co’s PD-1 inhibitor...
The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: American Express,...
Zacks via Yahoo Finance· 4 days agoAXP, Walmart Inc. WMT, Amazon.com Inc. AMZN, The Goldman Sachs Group Inc. GS and Merck & Co. Inc....
Insiders At Merck Sold US$12m In Stock, Alluding To Potential Weakness
Simply Wall St. via Yahoo Finance· 7 days agoThe fact that multiple Merck & Co., Inc. (NYSE:MRK) insiders offloaded a considerable amount of...
ASCO24: An early look at cancer drug study results
BioPharma Dive via Yahoo Finance· 1 day agoClinical trial abstracts posted Thursday ahead of this year’s ASCO meeting give a peek at anticipated datasets from Immunocore, Merus, J&J and Merck & Co...
Here's Why Merck (MRK) Stock Has Outperformed Industry YTD
Zacks via Yahoo Finance· 4 days agoYou can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Merck & Co., Inc....
Tango terminates USP1 inhibitor programme
Clinical Trials Arena via Yahoo Finance· 11 hours agoThe company’s market cap stands at $757.5m. Tango also planned to evaluate its therapy in combination with AstraZeneca’s and Merck & Co’s poly-ADP ribose...
